The Long Run with Luke Timmerman Podcast
1) Ep190: Neil Kumar on Building a Rare Disease Drug Company
Neil Kumar is founder and CEO of Palo Alto, Calif.-based BridgeBio Pharma, a rare disease drug developer.
2) Ep189: Marc Tessier-Lavigne on Reinventing Drug Discovery with AI
Marc Tessier-Lavigne, CEO of South San Francisco-based Xaira Therapeutics, on reinventing drug discovery with AI.
3) Ep188: Art Krieg on Innate Immune System Activators for Cancer
Art Krieg, founder and CEO of Zola Therapeutics, on developing innate immune system activators for cancer.
4) Ep187: Eric Fischer on Creating a New Class of Medicines
Eric Fischer, a professor at Dana-Farber Cancer Institute, on creating a new class medicines -- targeted protein degraders.
5) Ep186: Bruce Levine & Mags McCarthy on a Song About Science and Hope
Bruce Levine, a CAR-T cell therapy researcher at the University of Pennsylvania, and Mags McCarthy, a country music star, discuss their new song about science and hope for cancer patients.
6) Ep185: Dr. Lachelle Weeks on Predicting Leukemia Risk At Scale
Dr. Lachelle Weeks is a physician-scientist at Dana-Farber Cancer Institute working on a project to predict leukemia risk based on widely available blood samples.
7) Ep184: Jen Adair on Affordable, Accessible Gene & Cell Therapies
Jen Adair, professor and associate director of the Horae Gene Therapy Center at the University of Massachusetts Chan Medical School, on creating more affordable and accessible cell and gene therapies.
8) Ep183: Sabah Oney on CAR-T Cells Against Solid Tumors
Sabah Oney, CEO of Philadelphia and San Francisco-based Dispatch Biotherapeutics, on engineering CAR-T cells that can kill solid tumors.
9) Ep182: Andy Rachleff & Yung Lie on Creative Ways to Back Science
Andy Rachleff and Yung Lie, board chair and CEO of Damon Runyon Cancer Research Foundation, on creative ways to support science amid budget cuts.
10) Ep181: Claire Mazumdar on a Two-Pronged Attack Against Cancer
Claire Mazumdar, CEO of Boston-based Bicara Therapeutics, on developing a bifunctional antibody for head and neck cancer.